MINNEAPOLIS, Sept. 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced new advancements in its spatial biology portfolio for the RNAscope™ ISH technology and the Lunaphore COMET™. These solutions help researchers and pathologists bridge the gap between translational research and clinical applications by enabling the detection of RNA and protein biomarkers on the same tissue section.
RNAscope™ empowers pathologists and histologists to detect clinically relevant biomarkers—such as viral markers, secreted proteins, point mutations, and chromosomal translocations—within routine anatomic pathology workflows. COMET™ offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, accelerating spatial multiomic workflows and enabling deeper biological insights.
Scientific investigations presented this fall explore the potential of facilitating the diagnostic utility of these technologies. Studies include the use of RNAscope™ for assessing B-cell clonality with IGLL5 detection, and COMET™ for spatial profiling of lymphoid malignancies using a 21-plex seqIF™ panel. These findings demonstrate how spatial biology tools can be integrated into diagnostic workflows, especially in cases with limited tissue availability.
Bio-Techne will showcase these innovations at the National Society of Histotechnology (NSH) Convention, taking place September 26–30 in Long Beach, CA. Advanced Cell Diagnostics (ACD) and Lunaphore will exhibit at booths #139 and #427, respectively.
Presentations include:
Bio-Techne and Leica Biosystems continue to advance their partnership by co-hosting a waterfront reception at Parker's Lighthouse on September 28, offering attendees a chance to network and explore RNAscope assays on Leica BOND platforms.
"We are thrilled by the progress we've made in advancing traditional in situ hybridization," said Dr. Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne. "By working hand-in-hand with our customers and learning from the exceptional speakers at NSH, we are creating innovative tools that bring us closer to unlocking the molecular drivers of disease and transforming patient care."
Disclaimer:
The RNAscope probe for IGLL5 is an Analyte Specific Reagent. Analytical and performance characteristics have not been established.
RNAscope and COMET are For Research Use Only. Not for use in diagnostic procedures.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X or YouTube.
Contact:
Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
David Clair, Vice President, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$60.56 |
Daily Change: | 1.37 2.31 |
Daily Volume: | 2,062,613 |
Market Cap: | US$9.430B |
August 27, 2025 August 06, 2025 August 05, 2025 July 14, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load